- Record: found
- Abstract: found
- Article: not found
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
Eunice L Kwak
1 ,
Yung-Jue Bang ,
D Ross Camidge ,
Alice T Shaw ,
Benjamin Solomon ,
Robert G Maki ,
Sai-Hong I Ou ,
Bruce J Dezube ,
Pasi A Jänne ,
Daniel B Costa ,
Marileila Varella-Garcia ,
Woo-Ho Kim ,
Thomas J Lynch ,
Panos Fidias ,
Hannah Stubbs ,
Jeffrey A Engelman ,
Lecia V Sequist ,
WeiWei Tan ,
Leena Gandhi ,
Mari Mino-Kenudson ,
Greg C Wei ,
S Martin Shreeve ,
Mark J Ratain ,
Jeffrey Settleman ,
James G Christensen ,
Daniel A Haber ,
Keith Wilner ,
Ravi Salgia ,
Geoffrey I Shapiro ,
Jeffrey W Clark ,
A John Iafrate
Oct 28 2010
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Oncogenic fusion genes consisting of EML4 and anaplastic lymphoma kinase (ALK) are present in a subgroup of non-small-cell lung cancers, representing 2 to 7% of such tumors. We explored the therapeutic efficacy of inhibiting ALK in such tumors in an early-phase clinical trial of crizotinib (PF-02341066), an orally available small-molecule inhibitor of the ALK tyrosine kinase.